Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968175 · ClinicalTrials.gov registry record · NA
Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00968175 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants.
The verdict
NCT00968175, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine endoscopic ultrasound guided celiac plexus neurolysis (CPN) with analgesic therapy in patients with unresectable pancreatic cancer as it applies to decreasing the severity of abdominal pain when compared to analgesic therapy alone.
Interventions
- PROCEDURE Ultrasound guided celiac plexus neurolysis (CPN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968175
The ClinicalTrials.gov registry entry for NCT00968175 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ultrasound guided celiac plexus neurolysis (CPN) is the first listed.
NCT00968175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968175 about?
NCT00968175 is a clinical study titled "Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer". The purpose of this study is to examine endoscopic ultrasound guided celiac plexus neurolysis (CPN) with analgesic therapy in patients with unresectable pancreatic cancer as it applies to decreasing the severity of abdominal pain when compared to analgesic therapy alone.
What is the current status of trial NCT00968175?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2009-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00968175?
The interventions under investigation include: Ultrasound guided celiac plexus neurolysis (CPN) (PROCEDURE).
Who is sponsoring clinical trial NCT00968175?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.